Loading
A phase 2 trial of PF-08634404, Carboplatin, Paclitaxel / nab-paclitaxel in endometrial cancer and ovarian cancer, run by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., now recruiting.
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients is a phase 2 interventional study registered as NCT06522828 by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., with 80 participants planned, started 2024-10-10 and due to reach its primary completion in 2025-08. Interventions recorded: SSGJ-707, carboplatin, paclitaxel. Conditions listed: Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/